Cancer immunotherapy efficacy between two risk groups. (A) TME scores between different risk groups. (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.) (B) Stemness scores between different risk groups. (C) Differential expression of checkpoint-related genes between different risk groups. (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.) (D, E, F, and G) The correlation between treatment using immune checkpoint inhibitors and distinct risk groups.